Abigail Ogle
Nurse Practitioner · Fresno, CANPI 1154726248
Payments from drug & device makers
Across 231 payments — averaging $84.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$14K
- Amgen$2K
- Bayer$539
- Merck$431
- Medtronic$159
- GSK$155
- plus $1K from 19 others
What the payments were for
- Consulting fees$150%
- Food & beverage$5,09726%
- Education$700%
- Other$14,40074%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $14,400 |
| Amgen | 105 | $2,402 |
| Bayer | 25 | $539 |
| Merck | 18 | $431 |
| Medtronic | 4 | $159 |
| GSK | 3 | $155 |
| Novartis | 14 | $151 |
| Lilly USA, LLC | 9 | $138 |
| Pfizer | 8 | $131 |
| Scpharmaceuticals Inc. | 6 | $125 |
| Aimmune Therapeutics, Inc. | 1 | $124 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Lexicon Pharmaceuticals, Inc. | 5 | $99 |
| Actelion Pharmaceuticals US, Inc. | 2 | $94 |
| Amarin Pharma, Inc. | 4 | $76 |
| Boehringer Ingelheim | 3 | $72 |
| Baxter Healthcare | 3 | $70 |
| Boston Scientific | 1 | $54 |
| Abiomed | 2 | $49 |
| Smith+Nephew | 3 | $45 |
| Koya Medical, Inc. | 2 | $44 |
| Abbott | 1 | $29 |
| Philips North America LLC | 1 | $28 |
| Averitas Pharma Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,582 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 40 | $26,627 |
| EntrestoSacubitril/Valsartan | 21 | $21,280 |
| JardianceEmpagliflozin | 27 | $20,184 |
| MounjaroTirzepatide | 12 | $15,004 |
| EliquisApixaban | 13 | $11,547 |
| VascepaIcosapent Ethyl | 26 | $10,924 |
| KerendiaFinerenone | 12 | $9,873 |
| Icosapent Ethyl | 22 | $4,220 |
| Rosuvastatin Calcium | 27 | $518 |
| Metoprolol Succinate | 34 | $490 |
| ClopidogrelClopidogrel Bisulfate | 21 | $367 |
| Diclofenac Sodium | 12 | $356 |
| Gabapentin | 27 | $336 |
| Hydralazine Hcl | 14 | $319 |
| Amlodipine Besylate | 52 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $151 | $21,28021 claims |
| Boehringer IngelheimJardiance | $72 | $20,18427 claims |
| Lilly USA, LLCMounjaro | $138 | $15,00412 claims |
| PfizerEliquis | $131 | $11,54713 claims |
| BayerKerendia | $539 | $9,87312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Fresno
- Erica BedstedFresno$194K
- Sonja GrowcottFresno$31K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.